Log in to save to my catalogue

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2833999465

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In patients previously treated with covalent, irreversible BTK inhibitors, pirtobrutinib (a noncovalent, reversible BTK inhibitor) induced responses in 73%, with a median progression-free survival of nearly 20 months.

Alternative Titles

Full title

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2833999465

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2833999465

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2300696

How to access this item